Show simple item record

dc.contributor.authorMavaddat, Nasim
dc.contributor.authorAntoniou, Antonis C
dc.contributor.authorMooij, Thea M
dc.contributor.authorHooning, Maartje J
dc.contributor.authorHeemskerk-Gerritsen, Bernadette A
dc.contributor.authorNoguès, Catherine
dc.contributor.authorGauthier-Villars, Marion
dc.contributor.authorCaron, Olivier
dc.contributor.authorGesta, Paul
dc.contributor.authorPujol, Pascal
dc.contributor.authorLortholary, Alain
dc.contributor.authorBarrowdale, Daniel
dc.contributor.authorFrost, Debra
dc.contributor.authorEvans, D Gareth
dc.contributor.authorIzatt, Louise
dc.contributor.authorAdlard, Julian
dc.contributor.authorEeles, Ros
dc.contributor.authorBrewer, Carole
dc.contributor.authorTischkowitz, Marc
dc.contributor.authorHenderson, Alex
dc.contributor.authorCook, Jackie
dc.contributor.authorEccles, Diana
dc.contributor.authorvan Engelen, Klaartje
dc.contributor.authorMourits, Marian J E
dc.contributor.authorAusems, Margreet G E M
dc.contributor.authorKoppert, Linetta B
dc.contributor.authorHopper, John L
dc.contributor.authorJohn, Esther M
dc.contributor.authorChung, Wendy K
dc.contributor.authorAndrulis, Irene L
dc.contributor.authorDaly, Mary B
dc.contributor.authorBuys, Saundra S
dc.contributor.authorCaldes, Trinidad
dc.contributor.authorJakubowska, Anna
dc.contributor.authorSimard, Jacques
dc.contributor.authorSinger, Christian F
dc.contributor.authorTan, Yen
dc.contributor.authorOlah, Edith
dc.contributor.authorNavratilova, Marie
dc.contributor.authorForetova, Lenka
dc.contributor.authorGerdes, Anne-Marie
dc.contributor.authorRoos-Blom, Marie-José
dc.contributor.authorVan Leeuwen, Flora E
dc.contributor.authorArver, Brita
dc.contributor.authorOlsson, Håkan
dc.contributor.authorSchmutzler, Rita K
dc.contributor.authorEngel, Christoph
dc.contributor.authorKast, Karin
dc.contributor.authorPhillips, Kelly-Anne
dc.contributor.authorTerry, Mary Beth
dc.contributor.authorMilne, Roger L
dc.contributor.authorGoldgar, David E
dc.contributor.authorRookus, Matti A
dc.contributor.authorAndrieu, Nadine
dc.contributor.authorEaston, Douglas F
dc.contributor.authorBenitez, Javier 
dc.date.accessioned2021-05-06T08:00:50Z
dc.date.available2021-05-06T08:00:50Z
dc.date.issued2020-01-16
dc.identifier.citationBreast Cancer Res. 2020;22(1):8.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12888
dc.description.abstractThe effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.es_ES
dc.description.sponsorshipThe BCFR was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government or the BCFR. CNIO was partially supported by the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R and the Spanish Research Network on Rare Diseases (CIBERER). CNIO was also partially supported by FISPI16/00440. INHERIT was supported by the Canadian Institutes of Health Research for the 'CIHR Team in Familial Risks of Breast Cancer' program-grant #CRN-87521-and the Ministry of Economic Development, Innovation and Export Trade-grant #PSR-SIIRI-701. The PERSPECTIVE project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministere de l'Economie, de la Science et de l' Innovation du Quebec through Genome Quebec, and The Quebec Breast Cancer Foundation. Jacques Simard is a Chairholder of the Canada Research Chair in Oncogenetics. EMBRACE is supported by the Cancer Research UK grants C1287/A23382 and C1287/A16563. D. Gareth Evans is supported by an NIHR grant to the Biomedical Research Centre, Manchester (IS-BRC-1215-20007). The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and Elizabeth Bancroft are supported by the Cancer Research UK grant C5047/A8385. Ros Eeles is also supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Antonis C. Antoniou is funded by Cancer Research UK grants C12292/A20861 and C12292/A11174. MT is funded by the European Union Seventh Framework Program (2007-2013)/European Research Council (310018). The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no 110837, Rita K. Schmutzler). The national French cohort, GENEPSO, had been supported by a grant from the Fondation de France and the Ligue Nationale Contre le Cancer and is being supported by a grant from INCa as part of the European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012, no. 2014-008). HCSC was supported by CIBERONC 161200301 from ISCIII (Spain), partially supported by European Regional Development FEDER funds. The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organisation of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46, and the Transcan grant JTC 2012 Cancer 12-054. The IHCC was supported by Grant PBZ_ KBN_122/P05/2004 and ERA-NET TRANSAN JTC 2012 Cancer 12-054 (ERA-NET-TRANSCAN/07/2014). This work was supported by grants to kConFab and the kConFab Follow-Up Study from Cancer Australia (809195); the Australian National Breast Cancer Foundation (IF 17); the National Health and Medical Research Council (454508, 288704, 145684); the National Institute of Health U.S.A. (1RO1CA159868); the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; and the Cancer Foundation of Western Australia. KAP is an Australian National Breast Cancer Foundation fellow. MODSQUAD-Czech Republic, Brno, was supported by MH CZ -DRO (MMCI, 00209805) and by MEYS -NPS I -LO1413 to LF and MN. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745, NKFI OTKA K-112228, and the Norwegian EEA Financial Mechanism HU0115/NA/2008-3/OP-9. Lund-BRCA collaborators are supported by the Swedish Cancer Society, Lund Hospital Funds, and European Research Council Advanced Grant ERC-2011-294576. Stockholm-BRCA collaborators are supported by the Swedish Cancer Society. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshMutation es_ES
dc.subject.meshAdult es_ES
dc.subject.meshBRCA1 Protein es_ES
dc.subject.meshBRCA2 Protein es_ES
dc.subject.meshBreast Neoplasms es_ES
dc.subject.meshCohort Studies es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshIncidence es_ES
dc.subject.meshInternational Agencies es_ES
dc.subject.meshMenopause es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshProspective Studies es_ES
dc.subject.meshRisk Reduction Behavior es_ES
dc.subject.meshSalpingo-oophorectomy es_ES
dc.titleRisk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID31948486es_ES
dc.format.volume22es_ES
dc.format.number1es_ES
dc.format.page8es_ES
dc.identifier.doi10.1186/s13058-020-1247-4es_ES
dc.contributor.funderCancer Research UKes_ES
dc.contributor.funderNIH National Cancer Institute (NCI)es_ES
dc.contributor.funderUnited States Department of Health & Human Services National Institutes of Health (NIH) - USAes_ES
dc.contributor.funderMinisterio de Economia y Competividad (MINECO)es_ES
dc.contributor.funderEuropean Research Council (ERC)es_ES
dc.contributor.funderNorwegian EEA Financial Mechanismes_ES
dc.contributor.funderHungarian Research Grantses_ES
dc.contributor.funderMEYS -NPS Ies_ES
dc.contributor.funderMH CZ -DRO (MMCI)es_ES
dc.contributor.funderNational Health and Medical Research Council of Australiaes_ES
dc.contributor.funderAustralian National Breast Cancer Foundationes_ES
dc.contributor.funderCancer Australiaes_ES
dc.contributor.funderERA-NET TRANSAN JTC 2012 Canceres_ES
dc.contributor.funderTranscan grantes_ES
dc.contributor.funderBBMRI grantes_ES
dc.contributor.funderPink Ribbon grantses_ES
dc.contributor.funderNetherlands Organisation of Scientific Research grantes_ES
dc.contributor.funderKWF Kankerbestrijdinges_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderDeutsche Krebshilfees_ES
dc.contributor.funderNational Institute for Health Research (NIHR)es_ES
dc.contributor.funderEuropean Union Seventh Framework Program (2007-2013)es_ES
dc.contributor.funderMinistry of Economic Development, Innovation and Export Trade-grantes_ES
dc.contributor.funderCanadian Institutes of Health Research (CIHR)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1465-542Xes_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13058-020-1247-4.es_ES
dc.identifier.journalBreast cancer research : BCRes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Genética Humanaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2014-57680-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/310018es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CIBERONC161200301es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/294576es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FISPI16/00440es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/PBZ_ KBN_122/P05/2004es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional